Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy - Trial NCT06049134
Access comprehensive clinical trial information for NCT06049134 through Pure Global AI's free database. This Phase 4 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 4
Oct 06, 2023
Jul 31, 2025
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose
 versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment
 for B cell lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06049134
Non-Device Trial